METTL3 and urinary bladder carcinoma: Whereas inhibition of METTL3 expression in bladder cancer (BC) by cisplatin decreases m6A modification on granulocyte colony-stimulating factors (G-CSF) mRNA and the production of G-CSF, resulting in a reduced the number of fibrocytic MDSCs (f-MDSCs) during intra-arterial infusion chemotherapy (23).